The Royal Marsden NHS Foundation Trust shared on LinkedIn:
“Professor James Larkin, Consultant Medical Oncologist at The Royal Marsden and 2026 Scientific Co-Chair at ESMO, spoke with Peter M Goodwin from the Audio Journal of Oncology Podcast about the latest on the potential of cancer vaccines.
Personalized mRNA cancer vaccines for a range of tumour types are now seen as a realistic possibility thanks to mRNA technology already harnessed for treating melanoma in the phase III INTerpath-001 trial reported at the 2026 Annual Congress of the ESMO.
Listen here, or stream on your preferred podcast platform.
Episode Description
MADRID, Spain – Personalized mRNA cancer vaccines for a range of tumor types are now seen as a realistic possibility thanks to mRNA technology already harnessed for treating melanoma in the phase III INTerpath-001 trial reported at the 2026 Annual Congress of the European Society for Medical Oncology.
Peter Goodwin heard the latest on the potential of cancer vaccines from Scientific Co-Chair of ESMO 2026, James Larkin, Head of The Royal Marsden Skin Unit, and Joint Training Programme Director for Medical Oncology and Lead of the Cancer Immunotherapy Theme at The Royal Marsden’s Institute of Cancer Research NIHR Biomedical Research Centre, in London UK.”
You can also read: INTerpath-001 Trial: Personalized mRNA Cancer Vaccine in High-Risk Melanoma
